Impianto per trattare sostanze organiche e produrre un materiale fertilizzante

Un impianto (1) per trattare sostanze organiche fluide di scarto contenenti azoto ammoniacale e produrre un materiale fertilizzante a rilascio lento e controllato di azoto ammoniacale comprende: mezzi di miscelazione e sedimentazione (2), disposti per ricevere zeolitite e dette sostanze organiche fluide di scarto, formare una miscela contenente detta zeolitite e dette sostanze organiche fluide di scarto e consentire a detta miscela di sedimentare; mezzi vagliatori (3), disposti per vagliare detta miscela in uscita da detti mezzi di miscelazione e sedimentazione (2), in modo da separare detta zeolitite, arricchita in azoto ammoniacale e formante detto materiale fertilizzante a rilascio lento e controllato di azoto ammoniacale, da dette sostanze organiche fluide di scarto; mezzi di alimentazione (4), disposti per alimentare detti mezzi di miscelazione e sedimentazione (2) con dette sostanze organiche fluide di scarto

New markers for minimal residual disease detection in acute lymphoblastic leukemia

To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19+CD10+ B-cell progenitors (n = 4). Expression of 30 genes differentially expressed by ≥ 3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 105 BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity